

# Tycho Bismeijer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/724660/publications.pdf>

Version: 2024-02-01

12  
papers

398  
citations

1163117

8  
h-index

1372567

10  
g-index

13  
all docs

13  
docs citations

13  
times ranked

944  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. <i>Scientific Reports</i> , 2016, 6, 18517.	3.3	143
2	The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. <i>Breast Cancer Research</i> , 2017, 19, 99.	5.0	58
3	BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. <i>Molecular Oncology</i> , 2015, 9, 1528-1538.	4.6	54
4	A multilevel pan-cancer map links gene mutations to cancer hallmarks. <i>Chinese Journal of Cancer</i> , 2015, 34, 439-49.	4.9	38
5	Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression. <i>Radiology</i> , 2020, 296, 277-287.	7.3	37
6	Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER+/HER2 <sup>+</sup> Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6505-6515.	7.0	18
7	Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. <i>PLoS Computational Biology</i> , 2018, 14, e1006520.	3.2	13
8	Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo. <i>Nature Communications</i> , 2019, 10, 5034.	12.8	12
9	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. <i>Npj Breast Cancer</i> , 2021, 7, 31.	5.2	11
10	Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?. <i>European Journal of Radiology</i> , 2019, 121, 108705.	2.6	9
11	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. <i>British Journal of Cancer</i> , 0, , .	6.4	5
12	Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. <i>Breast</i> , 2021, 60, 230-237.	2.2	0